TMCnet News
Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis 2017: Key Players are Alkermes, Reata Pharmaceuticals, Incuron, Catabasis Pharmaceuticals - Research and MarketsThe "Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017" report has been added to Research and Markets' offering. The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation. According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source. /p>
Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others. NF-kB Inhibitors Therapeutics Pipeline Analysis:
Key Topics Covered: 1. Research Background 2. Research Methodology 3. Executive Summary 4. Pipeline Outlook 5. NF-Kappa B Inhibitors Therapeutics Pipeline Analysis by Phase (2017) 6. Clinical Trials Analysis 7. Competitive Landscape 8. Company Profiles 9. Appendix For more information about this report visit https://www.researchandmarkets.com/research/hwpzkw/nuclear?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005584/en/ |